Standardization and Clinical Utility of Thrombin-Generation Assays

ABSTRACT

Thrombin generation is a key process that determines the extent of a hemostatic plug or a thrombotic process. The ensuing thrombin burst is crucial for the formation of a stable fibrin clot. During its active life, thrombin exerts a multitude of highly regulated actions on the blood and the vessel wall, including the clotting of fibrinogen. The inappropriate generation of thrombin may lead to pathologic processes, foremost of which are hemorrhagic or thrombotic diseases. The coagulation system is usually investigated by means of two in vitro classic clotting tests, the activated partial thromboplastin time (APTT) and prothrombin time (PT), which assess only time to initiation of clot formation and do not entirely reflect global hemostatic balance. The APTT and PT permit identification of connectivity between the component activities identified as required for plasma coagulation and define the concept of intrinsic and extrinsic coagulation pathways, which converge at the point of formation of the prothrombinase complex. However, the mechanisms established by in vitro tests are not always mirrored in the human pathologies associated with bleeding or thrombosis. The recent development of newer tests based on the continuous registration of thrombin generation under in vitro conditions that mimic more closely what occurs in vivo prompt a reinvestigation of the balance between procoagulants and anticoagulants in patients with various hemostatic disorders. Thrombin-generation assays not only provide an overall assessment of hemostasis but also target potential extrahemostatic effects of the generated thrombin, a potent agonist of a multitude of cellular activation pathways. Moreover, estimation of an individual's thrombin-generation potential may correlate more closely with a hypercoagulable or hypocoagulable phenotype when compared with traditional coagulation tests. In this review, we discuss to what extent thrombin generation can be expected to reflect the clotting function of blood, the development and use of different thrombin-generation assay systems suitable for detecting changes in the kinetics of thrombin generation, and the clinical utility of thrombin generation.

Thrombin-generation assay - coagulation - thrombin - endogenous thrombin potential - APTT - PT

REFERENCES

• 1 MacFarlane R G. An enzyme cascade in the blood clotting mechanism and its function as a biochemical amplifier.  Nature. 1964;  202 498-499
• 2 Butenas S, van't Veer C, Mann K G. “Normal” thrombin generation.  Blood. 1999;  94 2169-2178
• 3 Dahlbäck B. Blood coagulation and its regulation by anticoagulant pathways: genetic pathogenesis of bleeding and thrombotic diseases.  J Intern Med. 2005;  257 209-223
• 4 Dargaud Y, Luddington R, Gray E et al.. Effect of standardization and normalization on imprecision of calibrated automated thrombography: an international multicentre study.  Br J Haematol. 2007;  139 303-309
• 5 Lippi G, Franchini M, Guidi G C. Diagnostic approach to inherited bleeding disorders.  Clin Chem Lab Med. 2007;  45 2-12
• 6 Mann K G, Brummel K, Butenas S. What is all that thrombin for?.  J Thromb Haemost. 2003;  1 1504-1514
• 7 Tripodi A, Salerno F, Chantarangkul V et al.. Evidence of normal thrombin generation in cirrhosis despite abnormal conventional coagulation tests.  Hepatology. 2005;  41 553-558
• 8 Mann K G, Butenas S, Brummel K. The dynamics of thrombin formation.  Arterioscler Thromb Vasc Biol. 2003;  23 17-25
• 9 Tripodi A, Martinelli I, Chantarangkul V et al.. The endogeneous thrombin potential and the risk of venous thromboembolism.  Thromb Res. 2007;  121 353-359
• 10 Furie B, Furie B C. In vivo thrombus formation.  J Thromb Haemost. 2007;  5(Suppl 1) 12-17
• 11 Hartert H. Blutgerinnungsstudien mit der Thrombelastographie, einem neuen Untersuchungsverfahren.  Klin Wochenschr. 1948;  26 577-583
• 12 Macfarlane R G, Biggs R. A thrombin generation test; the application in haemophilia and thrombocytopenia.  J Clin Pathol. 1953;  6 3-8
• 13 Hemker H C, Willems G M, Beguin S. A computer assisted method to obtain the prothrombin activation velocity in whole plasma independent of thrombin decay processes.  Thromb Haemost. 1986;  56 9-17
• 14 Hemker H C, Beguin S. Thrombin generation in plasma: its assessment via the endogenous thrombin potential.  Thromb Haemost. 1995;  74 134-138
• 15 Pitney W R, Dacie J V. A simple method of studying the generation of thrombin in recalcified plasma; application in the investigation of haemophilia.  J Clin Pathol. 1953;  6 9-14
• 16 Hemker H C, Wielders S, Kessels H, Béguin S. Continuous registration of thrombin generation in plasma, its use for the determination of the thrombin potential.  Thromb Haemost. 1993;  70 617-624
• 17 Hemker H C, Giesen P L, Ramjee M, Wagenvoord R, Béguin S. The thrombogram: monitoring thrombin generation in platelet-rich plasma.  Thromb Haemost. 2000;  83 589-591
• 18 Hemker H C, Al Dieri R, De Smedt E, Béguin S. Thrombin generation, a function test of the haemostatic-thrombotic system.  Thromb Haemost. 2006;  96 553-561
• 19 Hemker H C. Recollections on thrombin generation.  J Thromb Haemost. 2008;  6 219-226
• 20 Váradi K, Negrier C, Berntorp E et al.. Monitoring the bioavailability of FEIBA with a thrombin generation assay.  J Thromb Haemost. 2003;  1 2374-2380
• 21 Devreese K, Wijns W, Combes I, Van Kerckhoven S, Hoylaerts M F. Thrombin generation in plasma of healthy adults and children: chromogenic versus fluorogenic thrombogram analysis.  Thromb Haemost. 2007;  98 600-613
• 22 Butenas S, Branda R F, van't Veer C, Cawthern K M, Mann K G. Platelets and phospholipids in tissue factor-initiated thrombin generation.  Thromb Haemost. 2001;  86 660-667
• 23 Butenas S, Brummel K E, Paradis S G, Mann K G. Influence of factor VIIa and phospholipids on coagulation in “acquired” hemophilia.  Arterioscler Thromb Vasc Biol. 2003;  23 123-129
• 24 van Veen J J, Gatt A, Bowyer A E, Cooper P C, Kitchen S, Makris M. The effect of tissue factor concentration on calibrated automated thrombography in the presence of inhibitor bypass agents. 2008 Jan 9 [Epub ahead of print]
• 25 Butenas S, Brummel K E, Branda R F, Paradis S G, Mann K G. Mechanism of factor VIIa-dependent coagulation in hemophilia blood.  Blood. 2002;  99 923-930
• 26 Dielis A W, Castoldi E, Spronk H M et al.. Coagulation factors and the protein C system as determinants of thrombin generation in a normal population.  J Thromb Haemost. 2008;  6 125-131
• 27 Siegemund A, Petros S, Siegemund T, Scholz U, Seyfarth H J, Engelmann L. The endogenous thrombin potential and high levels of coagulation factor VIII, factor IX and factor XI.  Blood Coagul Fibrinolysis. 2004;  15 241-244
• 28 Gerotziafas G T, Depasse F, Busson J, Leflem L, Elalamy I, Samama M M. Towards a standardization of thrombin generation assessment: the influence of tissue factor, platelets and phospholipids concentration on the normal values of Thrombogram-Thrombinoscope assay.  Thromb J. 2005;  3 16
• 29 Ignjatovic V, Greenway A, Summerhayes R, Monagle P. Thrombin generation: the functional role of alpha-2-macroglobulin and influence of developmental haemostasis.  Br J Haematol. 2007;  138 366-368
• 30 Hemker H C, Al Dieri R, Béguin S. Thrombin generation assays: accruing clinical relevance.  Curr Opin Hematol. 2004;  11 170-175
• 31 Hemker H C, de Smedt E, Al Dieri R. The contribution of alpha(2)-macroglobulin thrombin to the endogenous thrombin potential.  Br J Haematol. 2007;  139 513
• 32 Luddington R, Baglin T. Clinical measurement of thrombin generation by calibrated automated thrombography requires contact factor inhibition.  J Thromb Haemost. 2004;  2 1954-1959
• 33 Silverberg M, Dunn J, Garen L, Kaplan A. Autoactivation of human Hageman factor. Demonstration utilizing a synthetic substrate.  J Biol Chem. 1980;  255 7281-7286
• 34 Hong J, Larsson A, Ekdahl K, Elgue G, Larsson R, Nilsson B. Contact between a polymer and whole blood: sequence of events leading to thrombin generation.  J Lab Clin Med. 2001;  138 139-145
• 35 Colman R W, Schmaier A H. Contact system: a vascular biology modulator with anticoagulant, profibrinolytic, antiadhesive, and proinflammatory attributes.  Blood. 1997;  90 3819-3843
• 36 Rand M D, Lock J B, van't Veer C, Gaffney D P, Mann K G. Blood clotting in minimally altered whole blood.  Blood. 1996;  88 3432-3445
• 37 Bidot L, Jy W, Bidot Jr C et al.. Microparticle-mediated thrombin generation assay: increased activity in patients with recurrent thrombosis.  J Thromb Haemost. 2008;  6 913-919
• 38 Pereira J, Alfaro G, Goycoolea M et al.. Circulating platelet-derived microparticles in systemic lupus erythematosus. Association with increased thrombin generation and procoagulant state.  Thromb Haemost. 2006;  95 94-99
• 39 Tappenden K A, Gallimore M J, Evans G, Mackie I J, Jones D W. Thrombin generation: a comparison of assays using platelet-poor and -rich plasma and whole blood samples from healthy controls and patients with a history of venous thromboembolism.  Br J Haematol. 2007;  139 106-112
• 40 Keularts I M, Zivelin A, Seligsohn U, Hemker H C, Béguin S. The role of factor XI in thrombin generation induced by low concentrations of tissue factor.  Thromb Haemost. 2001;  85 1060-1065
• 41 Kyrle P A, Mannhalter C, Béguin S et al.. Clinical studies and thrombin generation in patients homozygous or heterozygous for the G20210A mutation in the prothrombin gene.  Arterioscler Thromb Vasc Biol. 1998;  18 1287-1291
• 42 Regnault V, Béguin S, Wahl D et al.. Thrombinography shows acquired resistance to activated protein C in patients with lupus anticoagulants.  Thromb Haemost. 2003;  89 208-212
• 43 Gerotziafas G T, Chakroun T, Depasse F, Arzoglou P, Samama M M, Elalamy I. The role of platelets and recombinant factor VIIa on thrombin generation, platelet activation and clot formation.  Thromb Haemost. 2004;  91 977-985
• 44 Hemker H C, Giesen P, Al Dieri R et al.. Calibrated automated thrombin generation measurement in clotting plasma.  Pathophysiol Haemost Thromb. 2003;  33 4-15
• 45 Hézard N, Remy M G, Florent B, Nguyen P. Reliability of thrombin generation assay on frozen-thawed platelet-rich plasma: a reply.  Clin Chem. 2006;  52 2127-2128
• 46 Lippi G, Salvagno G L, Montagnana M, Guidi G C. Reliability of the thrombin-generation assay in frozen-thawed platelet-rich plasma.  Clin Chem. 2006;  52 1827-1828
• 47 Chantarangkul V, Clerici M, Bressi C, Giesen P L, Tripodi A. Thrombin generation assessed as endogenous thrombin potential in patients with hyper- or hypo-coagulability.  Haematologica. 2003;  88 547-554
• 48 Holub B J, Philbrick D J, Parbtani A, Clark W F. Dietary lipid modification of renal disorders and ether phospholipid metabolism.  Biochem Cell Biol. 1991;  69 485-489
• 49 Baglin T. The measurement and application of thrombin generation.  Br J Haematol. 2005;  130 653-661
• 50 Turecek P L, Váradi K, Keil B et al.. Factor VIII inhibitor-bypassing agents act by inducing thrombin generation and can be monitored by a thrombin generation assay.  Pathophysiol Haemost Thromb. 2003;  33 16-22
• 51 Seré K M, Rosing J, Hackeng T M. Inhibition of thrombin generation by protein S at low procoagulant stimuli: implications for maintenance of the hemostatic balance.  Blood. 2004;  104 3624-3630
• 52 Hackeng T M, Seré K M, Tans G, Rosing J. Protein S stimulates inhibition of the tissue factor pathway by tissue factor pathway inhibitor.  Proc Natl Acad Sci U S A. 2006;  103 3106-3111
• 53 Dargaud Y, Lienhart A, Meunier S et al.. Major surgery in a severe haemophilia A patient with high titre inhibitor: use of the thrombin generation test in the therapeutic decision.  Haemophilia. 2005;  11 552-558
• 54 Salvagno G L, Astermark J, Ekman M et al.. Impact of different inhibitor reactivities with commercial factor VIII concentrates on thrombin generation.  Haemophilia. 2007;  13 51-56
• 55 Berntorp E. VWF/FVIII complex and the management of patient with inhibitors: from laboratory to clinical practice.  Haemophilia. 2007;  13(Suppl 5) 69-72
• 56 Váradi K, Turecek P L, Schwarz H P. Thrombin generation assay and other universal tests for monitoring haemophilia therapy.  Haemophilia. 2004;  10 17-21
• 57 Livnat T, Martinowitz U, Zivelin A, Seligsohn U. Effects of factor VIII inhibitor bypassing activity (FEIBA), recombinant factor VIIa or both on thrombin generation in normal and haemophilia A plasma.  Haemophilia. 2008;  , Mar 25 [Epub ahead of print]
• 58 Lewis S J, Stephens E, Florou G et al.. Measurement of global haemostasis in severe haemophilia A following factor VIII infusion.  Br J Haematol. 2007;  138 775-782
• 59 Matsumoto T, Shima M, Takeyama M et al.. The measurement of low levels of factor VIII or factor IX in hemophilia A and hemophilia B plasma by clot waveform analysis and thrombin generation assay.  J Thromb Haemost. 2006;  4 377-384
• 60 Beltrán-Miranda C P, Khan A, Jaloma-Cruz A R, Laffan M A. Thrombin generation and phenotypic correlation in haemophilia A.  Haemophilia. 2005;  11 326-334
• 61 Mitka M. Guidelines for von Willebrand disease urge routine screening for bleeding.  JAMA. 2008;  299 1890
• 62 Rugeri L, Beguin S, Hemker C et al.. Thrombin-generating capacity in patients with von Willebrand's disease.  Haematologica. 2007;  92 1639-1646
• 63 Quiroga T, Goycoolea M, Giesen P L et al.. Thrombin generation in platelet-poor plasma is normal in patients with hereditary mucocutaneous haemorrhages.  Pathophysiol Haemost Thromb. 2003;  33 30-35
• 64 Keularts I M, Hamulyak K, Hemker H C, Béguin S. The effect of DDAVP infusion on thrombin generation in platelet-rich plasma of von Willebrand type 1 and in mild haemophilia A patients.  Thromb Haemost. 2000;  84 638-642
• 65 Al Dieri R, Peyvandi F, Santagostino E et al.. The thrombogram in rare inherited coagulation disorders: its relation to clinical bleeding.  Thromb Haemost. 2002;  88 576-582
• 66 Béguin S, Keularts I, Al Dieri R, Bellucci S, Caen J, Hemker H C. Fibrin polymerization is crucial for thrombin generation in platelet-rich plasma in a VWF-GPIb-dependent process, defective in Bernard-Soulier syndrome.  J Thromb Haemost. 2004;  2 170-176
• 67 Reverter J C, Béguin S, Kessels H, Kumar R, Hemker H C, Coller B S. Inhibition of platelet-mediated, tissue factor-induced thrombin generation by the mouse/human chimeric 7E3 antibody. Potential implications for the effect of c7E3 Fab treatment on acute thrombosis and “clinical restenosis”.  J Clin Invest. 1996;  98 863-874
• 68 Tripodi A, Mannucci P M. Laboratory investigation of thrombophilia.  Clin Chem. 2001;  47 1597-1606
• 69 Couturaud F, Duchemin J, Leroyer C, Delahousse B, Abgrall J F, Mottier D. Groupe d'Etude de la Thrombose de Bretagne Occidentale (G.E.T.B.O). Thrombin generation in first-degree relatives of patients with venous thromboembolism who have factor V Leiden. A pilot study.  Thromb Haemost. 2008;  99 223-228
• 70 Hézard N, Bouaziz-Borgi L, Remy M G, Nguyen P. Utility of thrombin-generation assay in the screening of factor V G1691A (Leiden) and prothrombin G20210A mutations and protein S deficiency.  Clin Chem. 2006;  52 665-670
• 71 Hron G, Kollars M, Binder B R, Eichinger S, Kyrle P A. Identification of patients at low risk for recurrent venous thromboembolism by measuring thrombin generation.  JAMA. 2006;  296 397-402
• 72 Simioni P, Tormene D, Spiezia L et al.. Inherited thrombophilia and venous thromboembolism.  Semin Thromb Hemost. 2006;  32 700-708
• 73 van Hylckama Vlieg A, Christiansen S C, Luddington R et al.. Elevated endogenous thrombin potential is associated with an increased risk of a first deep venous thrombosis but not with the risk of recurrence.  Br J Haematol. 2007;  138 769-774
• 74 Hankey G J. Stroke: how large a public health problem, and how can the neurologist help?.  Arch Neurol. 1999;  56 748-754
• 75 Anzej S, Bozic M, Antovic A et al.. Evidence of hypercoagulability and inflammation in young patients long after acute cerebral ischaemia.  Thromb Res. 2007;  120 39-46
• 76 Faber C G, Lodder J, Kessels F, Troost J. Thrombin generation in platelet-rich plasma as a tool for the detection of hypercoagulability in young stroke patients.  Pathophysiol Haemost Thromb. 2003;  33 52-58
• 77 Brummel-Ziedins K, Undas A, Orfeo T et al.. Thrombin generation in acute coronary syndrome and stable coronary artery disease: dependence on plasma factor composition.  J Thromb Haemost. 2008;  6 104-110
• 78 Orbe J, Zudaire M, Serrano R et al.. Increased thrombin generation after acute versus chronic coronary disease as assessed by the thrombin generation test.  Thromb Haemost. 2008;  99 382-387
• 79 Franchini M. Haemostasis and pregnancy.  Thromb Haemost. 2006;  95 401-413
• 80 Dati F, Pelzer H, Wagner C. Relevance of markers of hemostasis activation in obstetrics/gynecology and pediatrics.  Semin Thromb Hemost. 1998;  24 443-448
• 81 Perry Jr K G, Martin Jr J N. Abnormal hemostasis and coagulopathy in preeclampsia and eclampsia.  Clin Obstet Gynecol. 1992;  35 338-350
• 82 Bremme K, Blombäck M. Hemostatic abnormalities may predict chronic hypertension after preeclampsia.  Gynecol Obstet Invest. 1996;  41 20-26
• 83 Spaanderman M E, Van Beek E, Ekhart T H et al.. Changes in hemodynamic parameters and volume homeostasis with the menstrual cycle among women with a history of preeclampsia.  Am J Obstet Gynecol. 2000;  182 1127-1134
• 84 Rafik Hamad R, Curvers J, Berntorp E, Eriksson M, Bremme K.. Increased thrombin generation in women with a history of preeclampsia.  Thromb Res. 2008;  , May 21 [Epub ahead of print]
• 85 Tripodi A, Salerno F, Chantarangkul V et al.. Evidence of normal thrombin generation in cirrhosis despite abnormal conventional coagulation tests.  Hepatology. 2005;  41 553-558
• 86 Tripodi A, Primignani M, Chantarangkul V et al.. Thrombin generation in patients with cirrhosis: the role of platelets.  Hepatology. 2006;  44 440-445
• 87 Tripodi A, Ramenghi L A, Chantarangkul V et al.. Normal thrombin generation in neonates in spite of prolonged conventional coagulation tests.  Haematologica. 2008;  93 1256-1259
• 88 van Veen J J, Gatt A, Makris M. Thrombin generation testing in routine clinical practice: are we there yet?.  Br J Haematol. 2008;  142 889-903
• 89 Shima M, Matsumoto T, Ogiwara K. New assays for monitoring haemophilia treatment.  Haemophilia. 2008;  14(Suppl 3) 83-92